C

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Watchlist Manager
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Watchlist
Price: 18.88 CNY 0.48% Market Closed
Market Cap: ¥19.6B

Operating Margin

15.3%
Current
Improving
by 0.7%
vs 3-y average of 14.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
15.3%
=
Operating Income
¥1.7B
/
Revenue
¥10.9B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
15.3%
=
Operating Income
¥1.7B
/
Revenue
¥10.9B

Peer Comparison

Country Company Market Cap Operating
Margin
CN
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
19.5B CNY
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.4B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.8B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

Higher than 81% of companies in China
Percentile
81th
Based on 8 544 companies
81th percentile
15.3%
Low
-409 046.1% — -1.4%
Typical Range
-1.4% — 10.3%
High
10.3% — 876.4%
Distribution Statistics
China
Min -409 046.1%
30th Percentile -1.4%
Median 4.2%
70th Percentile 10.3%
Max 876.4%

China Resources Double-Crane Pharmaceutical Co Ltd
Glance View

Market Cap
19.6B CNY
Industry
Pharmaceuticals

In the dynamic landscape of China's pharmaceutical industry, China Resources Double-Crane Pharmaceutical Co Ltd emerges as a key player. It traces its roots back to the early 20th century, embodying a rich history of transformation and innovation. The company seamlessly integrates research, development, production, and sales, making it a formidable force in the healthcare sector. Primarily, it focuses on the production of chemical and biological drugs, catering to a wide range of therapeutic areas such as cardiovascular diseases, anti-infection solutions, and nutritional drugs. Through its comprehensive network, the company not only retains a robust domestic presence but also pushes its products into international markets, driving its revenue growth. Double-Crane's business model thrives on a blend of strategic partnerships and a strong emphasis on R&D. By collaborating with top research institutes and leveraging cutting-edge technology, it innovates new products to meet the rising demands of modern healthcare. The company’s substantial investment in R&D has allowed it to build a strong pipeline of proprietary drugs, ensuring a steady stream of products to boost its market position. With a keen eye on market trends and patient needs, China Resources Double-Crane continually optimizes its production processes and expands its distribution channels. This methodical approach enables the company to enhance its profitability while propelling it as a leader in the pharmaceutical industry.

Intrinsic Value
28.38 CNY
Undervaluation 33%
Intrinsic Value
Price
C
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
15.3%
=
Operating Income
¥1.7B
/
Revenue
¥10.9B
What is China Resources Double-Crane Pharmaceutical Co Ltd's current Operating Margin?

The current Operating Margin for China Resources Double-Crane Pharmaceutical Co Ltd is 15.3%, which is above its 3-year median of 14.6%.

How has Operating Margin changed over time?

Over the last 3 years, China Resources Double-Crane Pharmaceutical Co Ltd’s Operating Margin has increased from 12.4% to 15.3%. During this period, it reached a low of 12.4% on Aug 30, 2022 and a high of 15.7% on Dec 31, 2023.

Back to Top